Global /Singapore /Healthcare /Drug Manufacturers - General /BFK
chevron_leftBack
Pharmesis International Ltd. logo

Pharmesis International Ltd.

BFK
SGX: BFK Delayed
0.3550SGD 0%
0.2764 USD
As of 5 June 2026, Pharmesis International Ltd. has a market cap of $8.76M USD, ranking #41979 globally and #578 in Singapore. It ranks #3716 in the Healthcare sector, and #1206 in the Drug Manufacturers - General industry.
Global Rank
41979
Country Rank
578
Sector Rank
3716
Industry Rank
1206
Key Stats
Market Cap
$8.76MUSD
11.25M SGD
Enterprise Value
$10.39MUSD
13.35M SGD
Revenue (TTM)
$6.26MUSD
8.05M SGD
EBITDA (TTM)
-$431.35KUSD
-554.07K SGD
Net Income (TTM)
-$615.74KUSD
-790.93K SGD
EBITDA Margin
-6.9%
Profit Margin
-9.8%
PS Ratio
1.4
PB Ratio
1.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Xuedan Wu open_in_new
Employees
1,096
Founded
1996
Website
pharmesis.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0% 1.4% 22% -6.6% -22% -32%

News

Loading...

Markets

Exchange Ticker Price
Singapore Exchange
MIC: XSES
PRIMARY
BFK
Pharmesis International Ltd
ISIN: SG1BH6000003
Shares Out.:
31.7M1
TV:
SA:
YF:
GF:
BA:
BFK
MS:
0.3550 SGD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Pharmesis International Ltd.

Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People’s Republic of China. The company provides prescribed products and over-the-counter drugs. It offers western medicine products under the Kinna brand, including Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Compound Procaine hydrochloride to treat arteriosclerosi, menopausal symptoms, dyspepsia, and adynamia; Lianpushuangqing for acute inflammation; AFenKa to treat migraine, pain, headache, nasosinusitis, cold, muscle pain, menstrual pain, toothache, and arthritis; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for the rheumatoid arthritis and other rheumatic diseases treatment. The company also provides TCM formulated products under the Longlife brand name comprising Gulin Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice and clear heat and toxics; and Kang Gu Zeng Sheng for boosting the functions of kidney, as well as for increasing blood circulation and alleviating pain. In addition, it offers health supplement products, such as Mei Li Wei Ta to combat aging process and support bone health for women; Hao Xiu Xi to enhance sleep and regulate blood fats; Hao Zhuang Tai to regulate blood fats and fight fatique; and Qianlieman'an for promoting healthy prostate function and colon health, and supporting urinary function, as well as SHULINGHOU for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness. Further, the company distributes chemical drugs, biological raw products, TCM products, antibiotics, and antibiotic agents. Pharmesis International Ltd. was founded in 1996 and is based in Singapore.

Similar Companies

Industry: Drug Manufacturers - General (Singapore)
Name
Market Cap diff.
PE
$2.96B
3.8B SGD
34K%
14.3
$302.32M
388.34M SGD
3K%
-
$84.16M
108.1M SGD
861%
18.8
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
9M%
38.1
JNJ
$547.28B
6M%
26.4
ABBV
$360.63B
4M%
97.4
$324.68B
256.25B CHF
4M%
19.9
AZN
$289.43B
215.59B GBP
3M%
27.6
NOVN
$277.35B
218.9B CHF
3M%
20.5
chevron_leftBack